BioSpace - News

NEWSLETTERS
FREE Newsletters

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News

CAREER NETWORK
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
askHR
For Employers

DIVERSITY

HOTBEDS
Regional News
Biotech Bay™
Biotech Beach™
Genetown™
Pharm Country™
BioCapital™
BioMidwest™
Bio NC™
BioForest™
Southern Pharm™
BioCanada East™

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
BioPharm Insight

INDUSTRY EVENTS
Biotech Events

RESOURCES
Real Estate
New Business Opportunities

<< Back |

Torii, Toray Start to Co-Promote Hemoperfusion Absorption Column Toraymyxin for Removing Endotoxin

Tokyo, June 29, 2007 (JCN Newswire) - Torii Pharmaceutical Co., Ltd. and Toray Industries, Inc. announced that the companies would start joint promotion of Toraymyxin (PMX-20R, PMX-05R) from July 2, 2007 in Japan, a hemoperfusion absorption column for removing endotoxin, which was developed by Toray. Currently, Toray manufactures Toraymyxin which has been marketed by Toray Medical Co., Ltd., a wholly owned subsidiary of Toray.

Toraymyxin, a blood purification device (column), absorbs the bacterial toxin (endotoxin) that causes sepsis and septic shock using a special fiber. It consists of a plastic cylindrical container filled with a special fiber composite immobilized with the antibiotic polymyxin B, which has high affinity for endotoxin. Toray in 1993 received approval for manufacturing and marketing of the product from then the "Health and Welfare Ministry of Japan," and Toray Medical has been marketing it since 1994. Toraymyxin is designed to selectively absorb and remove endotoxin in the bloodstream, which is believed to be responsible for sepsis.

Torii, Toray and Toray Medical believe that the tie-up would enable provision of superior products and information faster and in a more detailed manner to medical experts who engage in urgent medical treatment and intensive care, leading to further contribution to improvements of patients as well as advancement of medical technology.

About Torii Pharmaceutical Co., Ltd.

Torii Pharmaceutical Co., Ltd., established in 1921, has manufactured and distributed ethical pharmaceutical products. In 1998, Torii became a member of the JT Group. To maximally leverage the synergy of the Group, R&D functions were transferred to JT and sales and marketing functions were transferred to Torii. Torii and JT continue to operate in close collaboration.

About Toray

Toray, a leading diversified chemicals corporate group, has been technology-focused since its foundation in 1926. The company's operations are underpinned by technological expertise in organic synthetic chemistry, polymer chemistry, and biochemistry - Toray's three core technologies. These innovative technologies have yielded "advanced materials" that Toray is now exploiting to provide customers with comprehensive solutions through Fibers and Textiles, Plastics and Chemicals, IT-related Products, Housing and Engineering, Pharmaceuticals and Medical Products, New Products and Other Business divisions. In FY2006, Toray had consolidated sales of 1,547 billion yen, and over 34,670 employees worldwide.

Contact:


Toray Industries
Corporate Communications Dept.
Tel: +81-3-3245-5179

June 29, 2007
Source: Torii Pharmaceutical Co., Ltd.
Source: Toray
Torii Pharmaceutical Co., Ltd. (TSE: 4551)
Toray (TSE: 3402) (U.S: TRYIY)
From the Japan Corporate News Network
http://www.japancorp.net
Topic: Press release summary